Neumora Therapeutics, Inc. (NMRA)

8,75 -0,75 (-7,89%) Börsenschluss: 04:00PM EDT

Neumora Therapeutics, Inc.

490 Arsenal Way
Suite 200
Watertown, MA 02472
United States
857 760 0900
https://www.neumoratx.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 120

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Paul L. Berns	Co-Founder & Executive Chairman	1,65M	N/A	1967
Mr. Henry O. Gosebruch	President, CEO & Director	3,33M	N/A	1973
Mr. Jason G. Duncan	Chief Legal Officer	315k	N/A	1974
Mr. Robert Lenz M.D., Ph.D.	Head of Research & Development	770,29k	N/A	1971
Ms. Carol Suh	Co-Founder & COO	N/A	N/A	1990
Dr. Robert Michael Poole FACP, M.D.	Co-Founder & Advisor	N/A	N/A	1957
Dr. Joshua Pinto Ph.D.	Chief Financial Officer	876,64k	N/A	1985
Mr. Michael Lee Milligan	Principal Accounting Officer	N/A	N/A	N/A
Dr. Rajesh Manchanda Ph.D.	Chief Technical Operations Officer	N/A	N/A	1966
Mr. Nicholas Brandon Ph.D.	Chief Scientific Officer	N/A	N/A	1974

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Corporate Governance

Neumora Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. Juni 2024, lautet 9. Die grundlegenden Scores sind Audit: 3, Vorstand: 9, Shareholderrechte: 8, Kompensation: 10.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.